
Global R&D Pipeline
My Favorite
Hot Targets:
ACP3
Back
Total number of drugs
14
Phase II and later clinical stages
7.1%
Involving companies
11
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA-based Vaccine Targeting Prostatic Acid Phosphatase(University of Wisconsin Madison) | DNA-based Vaccine Targeting Prostatic Acid Phosphatase(University of Wisconsin Madison) | Shared antigen vaccine DNA vaccine | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases | acid phosphatase 3 stimulants Immunostimulants | University of Wisconsin-Madison | Madison Vaccines, Inc.University of Wisconsin-Madison | Phase 2 | DNA-based Vaccine Targeting Prostatic Acid Phosphatase(University of Wisconsin Madison) | detail > | ||||||||||||
| HB-300 | HB-300 | Recombinant vector vaccine Therapeutic vaccine | Neoplasms Urogenital Diseases | acid phosphatase 3 modulators Prostate-specific antigen modulators Immunostimulants | HOOKIPA Pharma, Inc. | HOOKIPA Pharma, Inc. | Phase 1/2 | HB-300 | detail > | ||||||||||||
| [68]Ga-OncoACP3 | [68]Ga-OncoACP3 | Small molecule drug Diagnostic radiopharmaceuticals | Neoplasms Urogenital Diseases | acid phosphatase 3 inhibitors | Philochem AG | Philogen SpAPhilochem AG | Phase 1 | 68 Ga | [68]Ga-OncoACP3 | detail > | |||||||||||
| [177]Lu-OncoACP3 | [177]Lu-OncoACP3 | Small molecule drug Therapeutic radiopharmaceuticals | Neoplasms Urogenital Diseases | acid phosphatase 3 modulators | Philochem AG | Philochem AG | Preclinical | 177 Lu | [177]Lu-OncoACP3 | detail > | |||||||||||
| [18]F-OncoACP3 | [18]F-OncoACP3 | Small molecule drug Diagnostic radiopharmaceuticals | Neoplasms Urogenital Diseases | acid phosphatase 3 modulators | Philochem AG | Philochem AG | Preclinical | 18 F | [18]F-OncoACP3 | detail > | |||||||||||
| [225]Ac-OncoACP3 | [225]Ac-OncoACP3 | Small molecule drug Therapeutic radiopharmaceuticals | Neoplasms Urogenital Diseases | acid phosphatase 3 modulators | Philochem AG | Philochem AG | Preclinical | 225 Ac | [225]Ac-OncoACP3 | detail > | |||||||||||
| Anti ACP-3 antibody(Philochem) | Anti ACP-3 antibody(Philochem) | Monoclonal antibody | Neoplasms Urogenital Diseases | acid phosphatase 3 inhibitors | UniversitätsSpital ZürichPhilochem AG | Philochem AGUniversitätsSpital Zürich | Preclinical | Anti ACP-3 antibody(Philochem) | detail > | ||||||||||||
| ICT-801 | ICT-801 | CAR-T | Neoplasms Urogenital Diseases | acid phosphatase 3 inhibitors | Innovative Cellular Therapeutics Co., Ltd. | Innovative Cellular Therapeutics Co., Ltd. | Preclinical | ICT-801 | detail > | ||||||||||||
| RYZ-701 | RYZ-701 | Therapeutic radiopharmaceuticals | Neoplasms Urogenital Diseases | acid phosphatase 3 modulators | Rayzebio, Inc. | Rayzebio, Inc. | Preclinical | RYZ-701 | detail > | ||||||||||||
| RYZ-711 | RYZ-711 | Diagnostic radiopharmaceuticals | Neoplasms Urogenital Diseases | acid phosphatase 3 modulators | Rayzebio, Inc. | Rayzebio, Inc. | Preclinical | RYZ-711 | detail > |
Total 14 data
1
2


